LD 793 LR 1130(03)
An Act To Improve Accountability of Opioid Manufacturers
Fiscal Note for Senate Amendment " " to Committee Amendment " "
Sponsor: Pres. Jackson of Aroostook
Fiscal Note Required: Yes
Fiscal Note
Potential reduction in revenue received - Opiod Use Disorder Prevention and Treatment Fund
Fiscal Detail and Notes
Excluding manufacturers of an opioid product or products from the annual license fee for manufacturers of opioid medication under certain conditions may reduce the amount of revenue deposited into the Opioid Use Disorder Prevention and Treatment Fund from the annual license fee.  The amount cannot be estimated at this time.